Stockreport

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib [Yahoo! Finance]

Inhibikase Therapeutics, Inc.  (IKT) 
PDF BOSTON and ATLANTA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company d [Read more]